Browse > Article

Inhibition of Apoptosis is Responsible for the Acquired Resistance of K562 Cells to Cisplatin  

Lee, Soo-Yong (Biotransformation and Bioanalysis Research Center, Korea Institute of Science and Technology)
Kim, Dong-Hyun (Biotransformation and Bioanalysis Research Center, Korea Institute of Science and Technology)
Publication Information
Biomolecules & Therapeutics / v.12, no.2, 2004 , pp. 85-91 More about this Journal
Abstract
In all attempt to elucidate the role of apoptosis in drug resistance, cisplatin-resistant human chronic myelogenous leukemia (CML) K562 cells (K562/CDDP) were established and compared with drug sensitive parent cells (K562) in the induction of apoptosis. K562/CDDP cells were 5-fold more resistant to cisplatin compared to K562 cells. In addition, K562/CDDP cells were significantly more resistant to apoptois as judged by DNA fragmentation and DAPI staining. K562/CDDP cells exhibited decreased proleolytic activity of caspase-3 and this was further demonstrated by decreased cleavage of its substrate poly (ADP-ribose) polymerase (PARR- Western blot analysis showed that K562/CDDP cells had longer sustained levels of BCL-$X_L$ whereas no difference was noted in the level of Bcl-2. the translocation of Bax to mitochondria was significantly delayed in K562/CDDP cells. These results suggest that the reduced translocation of Bax and the sustained expression of BCL-$X_L$ may cause resistance to apoptosis through prevention of mitochondria release of cytochrome c, which subsequently induces reduction of caspase-3 activity and that this response is partly responsible for the acquired resistance to cisplatin ill K562 cells.
Keywords
cisplatin; apoptosis; resistance; K562 cell; Bax translocation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kim M., Lee Y. S., Mathew H. L., and Wurster R. D. (1997) Induction of apoptotic cell death in a neuroblastoma cell line by dibucaine. Exp. Cell Res. 231, 235-241   DOI   ScienceOn
2 Lee R. H., Song J. M., Park M. Y., Kang S. K., Kim Y. K., and Jung J. S. (2001) Cisplatin-induced apoptosis by translocation of endogenous BAX in mouse collecting duct cells. Biochem. Pharmacol. 62, 1013-1023   DOI   ScienceOn
3 Li J., Feng Q., Kim J. M., Schneidernlan D., Liston P., Li M., Vanderhyden B., Faught W., Fung M. F., Senterman M., Korneluk R. G., and Tsang B. K. (2001) Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 142, 370-380   DOI   ScienceOn
4 Breitschopf K., Haendeler J., Malchow P., Zeiher A. M., and Dimrneler S. (2000) Posttranslational modification of Bc1-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol.Cell BioI. 20, 1886-1896   DOI   ScienceOn
5 Chao D. T., and Korsmeyer S. J. (1998) Bc1-2 family: Regulators of cell death. Annual Rev. Immunol. 16, 395-419   DOI   ScienceOn
6 Chu G. (1994) Cellular responses to cisplatin. The roles of DNA binding proteins and DNA repair. J. BioI. Chem. 269, 787-790
7 Okazaki Y., Miura N., Satoh M., Imura N., and Naganuma A. (1998) Metallothionein-'mediated resistance to multiple drugs can be induced by several anticancer drug in mice. Biochem. Biophys. Res. Commun. 245, 815-818   DOI   ScienceOn
8 Oltvai Z. N., Milliman C. L., and Korsmeyer S. J. (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-619   DOI   ScienceOn
9 Perez R. P. (1998) Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer 34, 1535-1542,   DOI   ScienceOn
10 Reed J. C. (1998) Bcl-2 family proteins. Oncogene 17, 3225-3236   DOI   ScienceOn
11 Gonzalez·V. M., Fuertes M. A, Alonso C., and Perez J. M. (2001) Is Cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol. 59, 657-663
12 Harris M. H., and Thompson C. B. (2000) The role of the BcI-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 7, 1182-1191   DOI   ScienceOn
13 Huang L., Sowa Y., and Pardee A. B. (2000) Activation of the p21WAFI/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Spl sites. Oncogene 19, 5712-5719   DOI   ScienceOn
14 Joncourt F., Buser K., Altermatt H., Bacchi M., Oberli A., Cerny T. (1998) Multiple drug resistance parameter expression in ovarian cancer. Gynecol. Oncol. 70, 176-182
15 Kamarajan P., Sun N. K., Sun C. L., and Chao C. C. (2001) ApafI overexpression partially overcomes apoptotic resistance in a cisplatin-selected HeLa cell line. FEBS Lett. 505, 206-212   DOI   ScienceOn
16 Liu P. Q., Liu C. E., and Ames G. F. (1999) Modulation of ATPase activity by physical disengagement of the ATP-binding domains of an ABC transporter, the histidine permease. J. Biol. Chem. 274, 18310-18318   DOI
17 Kartner N., Everden-Porelle D., Bradley G., and Ling V. (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoelonal antibodies. Nature 316, 820-823   DOI   ScienceOn
18 Liu J. R., Fletcher B., Page C., Hu C., Nunez G., and Baker V. (1998) Bel-X$_L$ is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol. Oncol. 70, 398-403
19 Liu J. R, Opipari A. W., Tan L., Jiang Y., Zhang Y., Tang H., and Nunez G. (2002) Dysfunctional apoptosome activation in ovarian cancer: Implications for chemoresistance. Cancer Res. 62, 924-931
20 Miyashita T., and Reed J. C. (1995) Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell 80, 293-299   DOI   ScienceOn
21 Timrner-Bosscha H., Mulder N. H., and de Vries E. G. (1992) Modulation of cis-diamininedichloroplatinum(II) resistance: a review. Br. J. Cancer 66, 227-238   DOI   ScienceOn
22 Nagane M., Levitzki A., Gazit A., Gavenee W. K., and Huang H.-J. S. (1998) Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-X$_L$ and caspase-3-like proteases. Proc. Natl. Acad. Sci. USA 95, 5724-5729   DOI
23 Nomura M., Shimizu S., Ito T., Narita M., Matsuda H., and Tsujimoto Y. (1999) Apoptotic cytosol facilitates Bax translocation to mitochondrial that involves cytosolic factor regulated by Bcl-2. Cancer Res. 59, 5542-5548
24 Reed J. C. (2000) Mechanisms of apoptosis. Am. J. Pathol. 157, 1415-1430   DOI   ScienceOn
25 Walker P. R., Leblanc J., Smith B., Pandey S., and Sikorska M. (1999) Detection of DNA fragmentation and endonuclease in apoptosis. Methods 17, 329-338   DOI   ScienceOn
26 Finucane D. M., Bossy-Wetzel E., Waterhouse N. J., Cotter T. G., and Green D. R. (1999) Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-X$_L$. J. Bioi Chem. 274, 2225-2233   DOI   ScienceOn
27 Ganju N., and Eastman A. (2002) Bel-X$_L$ and Calyculin A prevent translocation of Bax to mitochondria during apoptosis. Biochem. Biophys. Res. Commun. 291, 1258-1264   DOI   ScienceOn
28 Germann U. A (1996) P-glycoprotein A mediator of multidrug resistance in tumour cells. Eur. J. Cancer 324, 927-944
29 el-Deiry W. S. (1997) Role of oncogenes in resistance and killing by cancer therapeutic agents. Curro Opin. Oncol. 9, 79-87